Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs

• Published in: Canadian veterinary journal 2006-10, Vol.47 (10), p.999-1002
• Main Authors: Scott, D.W, Peters, J, Miller, W.H. Jr
• Format: Article
• Language: English
• Subjects: adverse effects; Animals; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; antimicrobial agents; bacterial infections; Ciprofloxacin - adverse effects; Ciprofloxacin - analogs & derivatives; Ciprofloxacin - therapeutic use; disease severity; dog diseases; Dog Diseases - drug therapy; Dogs; drug evaluation; drug therapy; Female; Male; oral administration; orbifloxacin; pyoderma; Pyoderma - drug therapy; Pyoderma - veterinary; relapse; Scientific; Staphylococcal Infections - drug therapy; Staphylococcal Infections - veterinary; Staphylococcus intermedius; Time Factors; Treatment Outcome
• ISSN: 0008-5286

Orbifloxacin tablets were administered orally to 23 dogs with superficial and/or deep staphylococcal pyoderma. Response to therapy was excellent in 95.6% of the dogs. Duration of therapy varied from 21 to 40 days (average 29 days) for dogs having only superficial infections, and from 25 to 150 days (average 72 days) for dogs having deep infections. Relapses occurred in 18% of the dogs within a 3-month period. One dog developed a presumed adverse cutaneous drug reaction. Under the conditions of this study, orbifloxacin was an effective, safe, and convenient antibiotic for the treatment of superficial and deep staphylococcal pyoderma in dogs.